Compare Amgen, Inc. (AMGN) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Tapestry, Inc. — how do they compare? Amgen, Inc. trades at $356.92 (market cap $196.12B), while Tapestry, Inc. trades at $136.4 (market cap $28.43B). The key difference: Amgen, Inc. is far larger — about 6.9× Tapestry, Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | TPR | |
|---|---|---|
Market Cap | $196.12B | $28.43B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $160.49 |
52-Week Low | $271.18 | $95.69 |
Enterprise Value | $241.41B | $31.29B |
Dividend Yield | 2.77% | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
TPR trades at $140.73, up 0.57% today, with a bearish technical signal but strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS expected at $1.24. Valuation ratios are elevated (P/E 42.91, P/B 41.67), though profitability metrics like a 76.18% gross margin and 55.74% ROE remain robust. Recent news highlights digital growth and Gen Z engagement, with a $0.40 dividend paid in June 2026.
The outlook is mixed: bullish analyst consensus ($184.14 price target, 75.61% buy ratings) contrasts with technical bearishness and a high debt load. Key risks include sensitivity to consumer spending and execution of growth initiatives. Upside hinges on sustained earnings beats and margin expansion, while debt management and competitive pressures pose challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
